The present invention relates to novel ramipril crystalline particles with improved stability and bioavailability. More particularly, the present invention is directed to individually coated, single ramipril crystalline particles for pharmaceutical and biopharmaceutical applications in oral therapies that are stabilized against decomposition into degradation products, namely, ramipril-DKP and ramipril-diacid, during formulation and storage conditions. The present invention also relates to stabilized ramipril pharmaceutical compositions, novel anhydrous pharmaceutical grade ramipril powders, methods for improving ramipril bioavailability, and methods of manufacture and stabilization of ramipril formulations. The novel, anhydrous pharmaceutical grade ramipril powders and ramipril compositions and dosage forms formed therewith are useful in the treatment of cardiovascular disorders and have the advantage that they provide greater stability against decomposition into ramipril-DKPs and ramipril-diacids under formulation and storage conditions. In addition, they maintain consistent label ramipril potency over extended shelf-life and provide reduced in vivo variability in the bioavailability of ramipril among subjects when administered orally.
本发明涉及具有更高的稳定性和
生物利用度的新型
雷米普利结晶颗粒。更具体地说,本发明涉及单独包衣的单个
雷米普利结晶颗粒,用于制药和
生物制药的口服疗法,在配制和储存条件下可稳定地防止分解成降解产物,即
雷米普利-DKP 和
雷米普利-二酸。本发明还涉及稳定的
雷米普利药物组合物、新型无
水药用级
雷米普利粉末、提高
雷米普利生物利用度的方法以及
雷米普利制剂的制造和稳定方法。新型无
水药用级
雷米普利粉末和
雷米普利组合物及其形成的剂型可用于治疗心血管疾病,其优点是在配制和储存条件下具有更高的稳定性,不会分解成
雷米普利-DKPs 和
雷米普利二酸。此外,它们还能在较长的保质期内保持一致的
雷米普利药效,并减少口服
雷米普利时受试者体内
生物利用度的变化。